ABPI responds to Avastin case judgment

The Court has today made a judgment on the use of Avastin to treat a condition called wet age-related macular degeneration (wet AMD).

ABPI responds to Dr Ben Goldacre research on clinical trial transparency

The ABPI has responded to BMJ research into compliance with reporting the results of clinical trials. 

Have your say on proposed changes to the ABPI Code of Practice

Today sees the launch of a consultation on proposals to change the 2016 ABPI Code of Practice for the pharmaceutical industry.